Pre-Test Optimal Frontline Therapy of Myeloma Pre-Test 1. According to the NCCN guidelines, ____________ is recommended in combination with lenalidomide and dexamethasone based on improved overall survival of newly diagnosed transplant-ineligible MM patients in the phase 3 MAIA clinical trial. Bortezomib Carfilzomib Cyclophosphamide Daratumumab Unsure 2. Which of the following combinations has been shown to be a promising therapeutic option in newly-diagnosed MM based on 77% of patients experiencing a very good partial response in the phase 3 GMMG-HD7 trial? Daratumumab plus lenalidomide and dexamethasone Daratumumab plus lenalidomide, bortezomib, and dexamethasone Isatuximab plus lenalidomide, bortezomib, and dexamethasone Teclistamab plus lenalidomide Unsure 3. Negative _____________ status is associated with longer PFS and OS, and routine testing of this factor may provide early detection of treatment resistance. Cytokine biomarker Lactate dehydrogenase Minimal residual disease Soluble BCMA Unsure 4. How confident are you in your ability to select the appropriate combination regimen for frontline therapy in MM patients? Very confident Confident Somewhat confident Not very confident Not at all confident
